Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
48 studies found for:    "Zollinger-Ellison Syndrome"
Show Display Options
RSS Create an RSS feed from your search for:
"Zollinger-Ellison Syndrome"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome
Conditions: Gastrinoma;   Zollinger Ellison Syndrome
2 Completed Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer
Conditions: Islet Cell Adenoma;   Zollinger Ellison Syndrome
Intervention: Drug: Interferon
3 Completed Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas
Conditions: Islet Cell Adenoma;   Neoplasm Metastasis;   Zollinger Ellison Syndrome
Intervention: Drug: combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
4 Completed Treatment of Zollinger-Ellison Syndrome
Condition: Zollinger Ellison Syndrome
5 Completed Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome
Condition: Zollinger-Ellison Syndrome
Intervention: Drug: Esomeprazole magnesium (Nexium)
6 Enrolling by invitation YF476 and Type II Gastric Carcinoids
Condition: Zollinger-Ellison Syndrome
Intervention: Drug: YF476
7 Completed Evaluating Patients With Abnormal Levels of Gastric Acid
Conditions: Achlorhydria;   Gastrinoma;   Zollinger Ellison Syndrome
8 Completed The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid
Conditions: Gastrinoma;   Zollinger Ellison Syndrome
Interventions: Drug: Pantoprazole;   Drug: Omeprazole
9 Completed
Has Results
Treatment of Zollinger-Ellison Syndrome With Prevacid
Conditions: Zollinger-Ellison Syndrome;   Multiple Endocrine Neoplasia
Intervention: Drug: Lansoprazole (Prevacid)
10 Completed A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases
Conditions: Gastric Ulcer (GU);   Duodenal Ulcer (DU);   Anastomotic Ulcer (AU);   Non-erosive Reflux Esophagitis Disease (NERD);   Reflux Esophagitis (RE);   Zollinger-Ellison Syndrome
Interventions: Drug: D961H sachet 10 mg;   Drug: D961H capsule 10mg;   Drug: D961H capsule 20 mg
11 Completed Nexium Capsules Clinical Experience Investigation
Condition: Gastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Oesophagitis,"Non-erosive Reflux Disease, Zollinger-Ellison Syndrome
12 Not yet recruiting Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Conditions: Functional Pancreatic Neuroendocrine Tumor;   Malignant Somatostatinoma;   Merkel Cell Carcinoma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Carcinoid Tumor;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2A;   Multiple Endocrine Neoplasia Type 2B;   Neuroendocrine Neoplasm;   Non-Functional Pancreatic Neuroendocrine Tumor;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Adrenal Gland Pheochromocytoma;   Recurrent Merkel Cell Carcinoma;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Adrenal Cortex Carcinoma;   Stage III Thyroid Gland Medullary Carcinoma;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Adrenal Cortex Carcinoma;   Stage IV Merkel Cell Carcinoma;   Stage IVA Thyroid Gland Medullary Carcinoma;   Stage IVB Thyroid Gland Medullary Carcinoma;   Stage IVC Thyroid Gland Medullary Carcinoma;   Thymic Carcinoid Tumor;   VIP-Producing Neuroendocrine Tumor;   Well Differentiated Adrenal Cortex Carcinoma;   Zollinger Ellison Syndrome
Interventions: Drug: Capecitabine;   Drug: Temozolomide;   Drug: Veliparib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
13 Terminated Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   Gastrinoma;   Glucagonoma;   HER2-negative Breast Cancer;   Insulinoma;   Mucositis;   Oral Complications;   Pancreatic Polypeptide Tumor;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Recurrent Islet Cell Carcinoma;   Recurrent Renal Cell Cancer;   Somatostatinoma;   Stage III Renal Cell Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Renal Cell Cancer
Intervention: Drug: everolimus
14 Not yet recruiting Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: regorafenib;   Other: laboratory biomarker analysis
15 Withdrawn Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: dovitinib lactate;   Other: pharmacological study;   Other: laboratory biomarker analysis
16 Recruiting Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Liver Metastases;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: everolimus;   Other: placebo;   Other: laboratory biomarker analysis
17 Active, not recruiting Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Islet Cell Carcinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma
Interventions: Drug: temozolomide;   Drug: capecitabine;   Other: laboratory biomarker analysis
18 Active, not recruiting Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Pancreatic Cancer;   Somatostatinoma;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: capecitabine;   Drug: temozolomide;   Biological: bevacizumab
19 Active, not recruiting Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Pheochromocytoma;   Pancreatic Polypeptide Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Melanoma;   Recurrent Neuroendocrine Carcinoma of the Skin;   Recurrent Non-small Cell Lung Cancer;   Recurrent Pheochromocytoma;   Recurrent Renal Cell Cancer;   Somatostatinoma;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Melanoma;   Stage IV Non-small Cell Lung Cancer;   Stage IV Renal Cell Cancer;   Thyroid Gland Medullary Carcinoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: everolimus;   Drug: vatalanib;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Procedure: ultrasound imaging
20 Completed
Has Results
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Neuroendocrine Tumor;   Pancreatic Polypeptide Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Somatostatinoma;   WDHA Syndrome
Intervention: Drug: sorafenib tosylate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years